Asha Devi Kushwaha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Asha Devi Kushwaha has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Anjan K. Pradhan
Department of Oncology Science, University of Oklahoma College of Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma
13 shared publications - Carlos A. Valenzuela
Department of Oncology Science, University of Oklahoma College of Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma
13 shared publications - Channing J. Der
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
13 shared publications - Chunbo He
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA
13 shared publications - Dezhen Wang
School of Architecture, Chang’ an University, Xi’an, China
13 shared publications - Drew A. LaBreck
Department of Oncology Science, University of Oklahoma College of Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma
13 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Pharmacological inhibition of fatty acid oxidation sensitized pancreatic cancer cells to ERK inhibitor in vitro.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Pharmacological inhibition of fatty acid oxidation sensitized pancreatic cancer cells to ERK inhibitor in vitro.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
ERK inhibition upregulated fatty acid oxidation.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
ERK inhibition upregulated fatty acid oxidation.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
ERKi inhibition upregulated lipophagy and fatty acid oxidation via TFEB.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
ERKi inhibition upregulated lipophagy and fatty acid oxidation via TFEB.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Blood biochemistry indices from the CFPAC-1 tumor-bearing mice treated with MEK inhibitor, ranolazine, or their combinations.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Blood biochemistry indices from the CFPAC-1 tumor-bearing mice treated with MEK inhibitor, ranolazine, or their combinations.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Cell growth and lipidomic changes upon ERK inhibition in combination with inhibition of fatty acid oxidation.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Cell growth and lipidomic changes upon ERK inhibition in combination with inhibition of fatty acid oxidation.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Pharmacological inhibition of fatty acid oxidation in combination with ERK inhibitor impaired PDAC organoids growth.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Pharmacological inhibition of fatty acid oxidation in combination with ERK inhibitor impaired PDAC organoids growth.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Data from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by frequent KRAS mutations, which activate the MAPK pathway to promote PDAC progression. In this study, we explored metabolic vulnerabilities of PDAC by assessing initial metabolic reprogramming upon ERK inhibition using metabolomics, lipidomics, and isotope-tracing experiments. ERK inhibition enhanced lipid turnover and fatty acid (FA) oxidation while inhibiting glycolysis, glucose oxidation, and glutamine metabolism in PDAC cells. Moreover, lipophagy, but not cytosolic lipolysis, was responsible for the increased lipid turnover and FA oxidation upon ERK inhibition. Lipophagy and lipophagy-fueled FA oxidation were induced by increased nuclear translocation and activity of the transcription factor TFEB. Pharmacologic inhibition of FA oxidation in combination with KRASG12D/MEK/ERK inhibitors synergistically decreased the growth of PDAC cell lines and organoids. The combination decreased tumor burden and improved survival in orthotopic cell line and patient-derived xenograft PDAC models. Overall, this study provides mechanistic insights into the development of metabolic resistance to KRAS signaling inhibition and demonstrates that FA oxidation is a metabolic vulnerability following KRAS signaling inhibition that can be utilized as an effective therapeutic target to treat PDAC.Significance:Treating pancreatic cancer with inhibitors that target the KRAS pathway rewires metabolism by increasing lipophagy and fatty acid oxidation, which can be targeted to sensitize tumors to KRAS signaling inhibition.See related commentary by Delgado Herrera and Ferrer, p. 3374
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterized by frequent KRAS mutations, which activate the MAPK pathway to promote PDAC progression. In this study, we explored metabolic vulnerabilities of PDAC by assessing initial metabolic reprogramming upon ERK inhibition using metabolomics, lipidomics, and isotope-tracing experiments. ERK inhibition enhanced lipid turnover and fatty acid (FA) oxidation while inhibiting glycolysis, glucose oxidation, and glutamine metabolism in PDAC cells. Moreover, lipophagy, but not cytosolic lipolysis, was responsible for the increased lipid turnover and FA oxidation upon ERK inhibition. Lipophagy and lipophagy-fueled FA oxidation were induced by increased nuclear translocation and activity of the transcription factor TFEB. Pharmacologic inhibition of FA oxidation in combination with KRASG12D/MEK/ERK inhibitors synergistically decreased the growth of PDAC cell lines and organoids. The combination decreased tumor burden and improved survival in orthotopic cell line and patient-derived xenograft PDAC models. Overall, this study provides mechanistic insights into the development of metabolic resistance to KRAS signaling inhibition and demonstrates that FA oxidation is a metabolic vulnerability following KRAS signaling inhibition that can be utilized as an effective therapeutic target to treat PDAC.Significance:Treating pancreatic cancer with inhibitors that target the KRAS pathway rewires metabolism by increasing lipophagy and fatty acid oxidation, which can be targeted to sensitize tumors to KRAS signaling inhibition.See related commentary by Delgado Herrera and Ferrer, p. 3374
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
ERK inhibition downregulated fatty acid biosynthesis and glutamine metabolism.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
ERK inhibition downregulated fatty acid biosynthesis and glutamine metabolism.
- Open Access
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Mouse weight and blood biochemistry indices from the KPC1245 tumor-bearing mice treated with ERK inhibitor, MEK inhibitor, KRAS G12D inhibitor, ranolazine, or their indicated combinations.
- 15 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer
Mouse weight and blood biochemistry indices from the KPC1245 tumor-bearing mice treated with ERK inhibitor, MEK inhibitor, KRAS G12D inhibitor, ranolazine, or their indicated combinations.